Solianis Monitoring AG Participates in the Pioneering EU-Project REACTION for Improved Diabetes Management
By Solianis Monitoring Ag, PRNEWednesday, March 31, 2010
ZURICH, April 1, 2010 - Solianis Monitoring AG is an important project partner in the
development of REACTION, a professional service platform for doctors,
caregivers and patients to improve the long term management of diabetes.
The objective of the project is to improve glucose control in
insulin requiring patients with diabetes by combining continuous glucose
monitoring with intelligent Information and Communication Technology. It is
funded by the European Union under the Framework 7 program with a total
budget of EUR 11 Mio. The continuous glucose monitoring systems will connect
various hospitals and advanced mathematical systems through a wireless
network to assess patients' conditions and provide therapy recommendations.
These integrated services aim to assist healthcare professionals,
non-professional caretakers and patients in successful disease management in
order to improve the long term outcome for patients with diabetes. Solianis
will support the platform with its know-how and its non-invasive continous
glucose monitoring system.
"We are very excited to engage in this project," says Mario
Stark, CEO of Solianis. "This cooperation gives us the opportunity not only
to leverage the advanced communication capabilities of our innovative system
but also to get closer to our main goal of improving the quality of life of
patients with diabetes."
Solianis Monitoring AG is a Swiss medical device company
developing an innovative non-invasive continuous glucose monitoring system
for people with diabetes, their relatives and health care professionals. Its
unique and proprietary technology is integrated in a Multisensor Glucose
Monitoring System which continuously delivers information on glucose
variations.
REACTION stands for "Remote Accessibility to Diabetes
Management and Therapy in Operational Healthcare Networks" and is a 4-years
research project funded by the European Commission as part of the 7th
Framework Program on Personal Health Systems. Read more about the project on
www.reaction-project.eu .
Contacts: Media Micaela Wochner Phone: +41-44-306-80-29 Mobile: +41-79-431-79-34 Micaela.wochner@solianis.com www.solianis.com Investors: Mario Stark Phone: +41-443-306-80-40 Mobile: +41-79-542-88-74 Mario.stark@solianis.com
Contacts: Media: Micaela Wochner, Phone: +41-44-306-80-29, Mobile: +41-79-431-79-34, Micaela.wochner at solianis.com; Investors: Mario Stark, Phone: +41-443-306-80-40, Mobile: +41-79-542-88-74, Mario.stark at solianis.com
Tags: April 1, Solianis Monitoring AG, Switzerland, Zurich